Product Description
Mechanisms of Action: Histamine Antagonist,AChR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Belgium | Brazil | Bulgaria | Egypt | France | Indonesia | Israel | Jordan | Korea | Lebanon | Morocco | Switzerland | Taiwan | Tunisia | United Arab Emirates | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: EMS
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
OGPGEMS0110 | P3 |
Completed |
Other |
2013-09-30 |